Company intelligence / Profile preview

Immunome

Exton, Pennsylvania, United Statesimmunome.com ↗

Ownership: Public · IMNM
Employees: ~11
Development stage: Phase 1

Overview

Immunome has advanced to the clinical stage with a pipeline of targeted cancer therapies. Their approach leverages patient-derived immune responses to discover novel antigens and corresponding antibodies. The company’s lead programs include antibody-drug conjugates (ADCs) and other immunotherapies targeting difficult-to-treat cancers. Detailed clinical results are not specified in public summaries as of June 2025

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodyRadioligand therapyImmunotherapy
Industry: Biotech

Drug pipeline

17 assets

varegacestat

16 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.4B
Total revenue: $0
Enterprise value: $1.9B

Beyond the preview

Go deeper on Immunome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunome.

Explore the full profile